Aptamer-Conjugated Extracellular Nanovesicles for Targeted Drug Delivery.

Extracellular nanovesicles (ENV) released by many cells contain lipids, proteins, and nucleic acids that contribute to intercellular communication. ENVs have emerged as biomarkers and therapeutic targets but they have also been explored as drug delivery vehicles. However, for the latter application, clinical translation has been limited by low yield and inadequate targeting effects. ENV vectors with desired targeting properties can be produced from parental cells engineered to express membrane-bound targeting ligands, or they can be generated by fusion with targeting liposomes; however, neither approach has met clinical requirements. In this study, we demonstrate that mechanical extrusion of approximately 107 cells grafted with lipidated ligands can generate cancer cell-targeting ENV and can be prepared in approximately 1 hour. This rapid and economic approach could pave the way for clinical implementation in the future.Significance: A new and rapid method for production of drug-targeting nanovesicles has implications for cancer treatment by chimeric antigen receptor T cells and other therapies. Cancer Res; 78(3); 798-808. ©2017 AACR.

[1]  Hélder A Santos,et al.  Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake. , 2014, Biomaterials.

[2]  Sung Ho Ryu,et al.  A Nucleolin-Targeted Multimodal Nanoparticle Imaging Probe for Tracking Cancer Cells Using an Aptamer , 2010, Journal of Nuclear Medicine.

[3]  M Kersaudy-Kerhoas,et al.  Exosome isolation: a microfluidic road-map. , 2015, Lab on a chip.

[4]  Waseem Asghar,et al.  Velocity effect on aptamer-based circulating tumor cell isolation in microfluidic devices. , 2011, The journal of physical chemistry. B.

[5]  Laurence Zitvogel,et al.  Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.

[6]  A. Kesselheim,et al.  The FDA, Juno Therapeutics, and the ethical imperative of transparency , 2016, British Medical Journal.

[7]  A. Hovanessian,et al.  Surface Expressed Nucleolin Is Constantly Induced in Tumor Cells to Mediate Calcium-Dependent Ligand Internalization , 2010, PloS one.

[8]  Dong Wei,et al.  Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer , 2008, Molecular Therapy.

[9]  Gregory L. Szeto,et al.  Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.

[10]  Louai Labanieh,et al.  Nucleic acid aptamers in cancer research, diagnosis and therapy. , 2015, Chemical Society reviews.

[11]  Yangxin Li,et al.  Transport of microRNAs via exosomes , 2015, Nature Reviews Cardiology.

[12]  Andrew D Ellington,et al.  Nanotextured substrates with immobilized aptamers for cancer cell isolation and cytology , 2012, Cancer.

[13]  H. Poulsen,et al.  Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies , 2012, BioDrugs.

[14]  M. Michael,et al.  Hypoxic enhancement of exosome release by breast cancer cells , 2012, BMC Cancer.

[15]  Allan Svendsen,et al.  Bionanoconjugation via click chemistry: The creation of functional hybrids of lipases and gold nanoparticles. , 2006, Bioconjugate chemistry.

[16]  J. Le Pecq,et al.  Increasing vaccine potency through exosome antigen targeting. , 2011, Vaccine.

[17]  S. el-Sahrigy,et al.  Comparison between magnetic activated cell sorted monocytes and monocyte adherence techniques for in vitro generation of immature dendritic cells: an Egyptian trial , 2015, Central-European journal of immunology.

[18]  M. Hemler Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. , 2003, Annual review of cell and developmental biology.

[19]  P. Bouvet,et al.  AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. , 2010, Current opinion in molecular therapeutics.

[20]  Raghu Kalluri,et al.  Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer , 2017, Nature.

[21]  Myung Soo Kim,et al.  Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[22]  G. Schuler,et al.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. , 1999, Journal of immunological methods.

[23]  Gunther Hartmann,et al.  SiRNA delivery with exosome nanoparticles , 2011, Nature Biotechnology.

[24]  M. Wood,et al.  Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes , 2011, Nature Biotechnology.

[25]  J. Eberwine,et al.  Mammalian cell transfection: the present and the future , 2010, Analytical and bioanalytical chemistry.

[26]  Hakho Lee,et al.  Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor , 2014, Nature Biotechnology.

[27]  Yoshihiro Sasaki,et al.  Engineering hybrid exosomes by membrane fusion with liposomes , 2016, Scientific Reports.

[28]  Shinobu Ueda,et al.  Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  R. Schiffelers,et al.  Exosome mimetics: a novel class of drug delivery systems , 2012, International journal of nanomedicine.

[30]  Jian Song,et al.  A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. , 2014, Biomaterials.

[31]  J. Friedberg,et al.  Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1 , 2016 .

[32]  Andrew D. Ellington,et al.  Surface-immobilized aptamers for cancer cell isolation and microscopic cytology. , 2010, Cancer research.

[33]  Thomas J. Anchordoquy,et al.  Surface Functionalization of Exosomes Using Click Chemistry , 2014, Bioconjugate chemistry.

[34]  Olivier Lantz,et al.  Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial , 2005, Journal of Translational Medicine.

[35]  Gong Cheng,et al.  Rapid magnetic isolation of extracellular vesicles via lipid-based nanoprobes , 2017, Nature Biomedical Engineering.

[36]  Maria Ericsson,et al.  Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. , 2014, ACS nano.

[37]  Carla Oliveira,et al.  Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. , 2016, ACS nano.

[38]  Christian Pilarsky,et al.  Glypican-1 identifies cancer exosomes and detects early pancreatic cancer , 2015, Nature.

[39]  Jing Xu,et al.  DSPE-PEG: a distinctive component in drug delivery system. , 2015, Current pharmaceutical design.

[40]  Xin Hou,et al.  Blood Exosomes Endowed with Magnetic and Targeting Properties for Cancer Therapy. , 2016, ACS nano.

[41]  Aled Clayton,et al.  Antigen‐presenting cell exosomes are protected from complement‐mediated lysis by expression of CD55 and CD59 , 2003, European journal of immunology.

[42]  J. Le Pecq,et al.  A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer , 2005, Journal of Translational Medicine.

[43]  Gert Storm,et al.  Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system , 1995 .

[44]  B. Matuszewski,et al.  Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. , 2003, Analytical chemistry.

[45]  Gemma K. Alderton Diagnosis: Fishing for exosomes , 2015, Nature Reviews Cancer.

[46]  R. Schiffelers,et al.  Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[47]  Jaesung Park,et al.  Nanovesicles engineered from ES cells for enhanced cell proliferation. , 2014, Biomaterials.